Keith Dionne is CEO of Luxa Biotechnology LLC, a company developing novel biotherapeutics. Dionne earned his undergraduate degree from Brigham Young University before completing his Ph.D. in chemical engineering at MIT, where his fellowship began in 1986. His doctoral research focused on bioartificial organ design and biomaterials, including pioneering work on encapsulated islet cell transplantation as a potential treatment for type 1 diabetes. He subsequently held senior positions in the biotechnology industry, including at Hana Biosciences and other cell therapy companies, before leading Luxa Biotechnology.
Keith Dionne, PhD
1986 HERTZ FELLOW
MAKING HISTORY
EDUCATION
Graduate Studies
Massachusetts Institute of Technology
Chemical Engineering
Graduate Thesis
Effect of Hypoxia on Insulin Secretion and Viability of Pancreatic Islet Tissue
Undergraduate Studies
Brigham Young University
IMPACT STORY
Lorem ipsum dolor sit amet, consecteta aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in.ur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in.
READ MORE
GET IN TOUCH WITH Keith Dionne
Lorem ipsum dolor sit amet, consecteta aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in.ur adipiscing elit,
